



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Correspondence

Convalescent plasma therapy in the treatment of COVID-19: Some considerations: Correspondence



ARTICLE INFO

Keywords:
 COVID-19
 Convalescent
 Plasma

Dear Editor, I would like to share ideas on “Convalescent plasma therapy in the treatment of COVID-19: practical considerations: Correspondence.” is very interesting [1]. Islam et al. noted that “*While we await trial results, we recommend that CPT be considered for patients severely ill with COVID-19 upon hospitalization* [1].” Convalescent plasma therapy is still not scientifically proven for its usefulness and safety. In fact, Islam et al. already mentioned for considerations on possible problem due to pathogen contamination in convalescent plasma [1]. At present, there is still no scientific proof that the presently use plasma preparation technique in all blood banks can successfully remove all pathogens. There are many other classic therapeutic options that might pose lower risk for management of COVID-19 such as the use of classic drug, hydroxychloroquine. Finally, whether the convalescent plasma can act against the novel coronavirus or not still requires further studies. There are some evidences on possible repeated COVID-19 infection in patients recovered from COVID-19 [2,3]. This can imply that there is a chance that there will be no protective immunity in plasma of patients recovered from a COVID-19 illness.

Sources of funding

None.

Ethical approval

Not applicable.

Unique identifying number (UIN)

1. Name of the registry: not applicable
2. Unique Identifying number or registration ID: not applicable
3. Hyperlink to your specific registration (must be publicly accessible and will be checked):

Author contribution

Wiwanitkit 100%.

Guarantor

Professor Viroj Wiwanitkit.

Provenance and peer review

Not Commissioned, internally reviewed.

Data statement

Not applicable.

Declaration of competing interest

None.

References

- [1] A. Islam, S. Rafiq, S. Karim, I. Laher, H. Rashid, Convalescent plasma therapy in the treatment of COVID-19: practical considerations: Correspondence, *Int. J. Surg.* S1743–9191 (20) (2020 Jun 2) 30462–30463.
- [2] V.T. Hoang, T.L. Dao, P. Gautret, Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19, *J. Med. Virol.* (2020 May 25), <https://doi.org/10.1002/jmv.26056> Online ahead of print.
- [3] M. Bongiovanni, F. Basile, Re-infection by COVID-19: a real threat for the future management of pandemia? *Inf. Disp.* (2020 May 21) 1–2, <https://doi.org/10.1080/23744235.2020.1769177>.

Viroj Wiwanitkit
 Dr DY Patil University, Pune, India
 E-mail address: vwiroj@yahoo.com.

DOI of original article: <https://doi.org/10.1016/j.ijvs.2020.05.079>

<https://doi.org/10.1016/j.ijvs.2020.06.029>

Received 10 June 2020; Accepted 13 June 2020

Available online 22 June 2020

1743-9191/ © 2020 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.